Review for 10.1186/s12876-019-1056-3 (2019)

Reviewer’s report
Title:  Cefuroxime,  levofloxacin,  esomeprazole,  and  bismuth  as  first-line  Helicobacter  pylori  
eradication therapy in patients allergic to penicillin
Version: 4 Date: 02 Jul 2019
Reviewer: Chao-Hung Kuo
Reviewer's report:
Thank you for your efforts on the added paragraph according to my suggestions. The modified table  
and discussion content make your manuscript more complete. 
The table 3 showed univariate and multi-variates data with p value and this makes readers to get more  
understanding of the significance of your result. Also, you make clear that all patients are Tx-naïve and  
emphasize the lack of previous antibiotics history in your limitation part. That explanation makes your  
result more realistic. 
However , one minor revision needs to be done. Your new references 9-12 are about the eradications  
rates of patients with allergy to penicillin. However, the references are from the same group, Gisbert JP  
from Spain. Could you please  provide the reference originating from mainland China ? the local data is  
more convincing and more realistic when it comes to Hp eradication. 
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional  
statistical review?
If  an  additional  statistical  review  is  recommended,  please  specify  what  aspects  require  further  
assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If  
your reply is yes to any, please give details below.
I declare that I have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included on my  
report to the authors and, if the manuscript is accepted for publication, my named report including any 
attachments I upload will be posted on the website along with the authors' responses. I agree for my 
report to be made available under an Open Access Creative Commons CC-BY license 
(http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments which I do not wish to 
be included in my named report can be included as confidential comments to the editors, which will not  
be published.
I agree to the open peer review policy of the journal